Inogen, Inc. (NASDAQ:INGN - Get Free Report) was the target of a significant increase in short interest in the month of January. As of January 31st, there was short interest totalling 798,600 shares, an increase of 8.8% from the January 15th total of 734,000 shares. Based on an average daily trading volume, of 224,800 shares, the short-interest ratio is currently 3.6 days.
Analyst Ratings Changes
Several research firms have issued reports on INGN. Needham & Company LLC restated a "hold" rating on shares of Inogen in a research report on Thursday, January 30th. StockNews.com upgraded shares of Inogen from a "hold" rating to a "buy" rating in a research report on Monday, February 10th.
Check Out Our Latest Research Report on INGN
Hedge Funds Weigh In On Inogen
Several hedge funds and other institutional investors have recently modified their holdings of INGN. Royce & Associates LP raised its stake in shares of Inogen by 167.4% during the third quarter. Royce & Associates LP now owns 51,891 shares of the medical technology company's stock valued at $503,000 after acquiring an additional 32,482 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Inogen by 312.5% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 174,625 shares of the medical technology company's stock valued at $1,694,000 after acquiring an additional 132,287 shares during the last quarter. BNP Paribas Financial Markets raised its stake in shares of Inogen by 13.9% during the third quarter. BNP Paribas Financial Markets now owns 42,137 shares of the medical technology company's stock valued at $409,000 after acquiring an additional 5,131 shares during the last quarter. Verition Fund Management LLC bought a new position in Inogen in the third quarter worth about $106,000. Finally, Paloma Partners Management Co bought a new position in Inogen in the third quarter worth about $126,000. 89.94% of the stock is owned by institutional investors.
Inogen Stock Down 3.4 %
Shares of NASDAQ:INGN traded down $0.37 during midday trading on Thursday, hitting $10.30. 318,878 shares of the stock traded hands, compared to its average volume of 262,972. The stock has a market capitalization of $245.44 million, a PE ratio of -4.58 and a beta of 1.02. The business's 50 day moving average is $10.15 and its two-hundred day moving average is $10.27. Inogen has a one year low of $5.82 and a one year high of $13.33.
About Inogen
(
Get Free Report)
Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Read More
Before you consider Inogen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inogen wasn't on the list.
While Inogen currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
